Literature DB >> 32482664

Splice of Life for Cancer: Missplicing of PPP2R5A by Mutant SF3B1 Leads to MYC Stabilization and Tumorigenesis.

Caitlin M O'Connor1, Goutham Narla2.   

Abstract

Although mutations in SF3B1 are the most common RNA-splicing factor mutations in cancer, determining the downstream missplicing events that drive tumorigenesis has remained challenging. Liu and colleagues present a model by which mutant SF3B1 tumors displayed high levels of oncogenic MYC activity through the missplicing of PP2A-B56α, a key post-translational regulator of MYC stability, providing a new therapeutic target and driver of SF3B1-mediated tumorigenesis.See related article by Liu et al., p. 806. ©2020 American Association for Cancer Research.

Entities:  

Mesh:

Substances:

Year:  2020        PMID: 32482664      PMCID: PMC8162994          DOI: 10.1158/2159-8290.CD-20-0358

Source DB:  PubMed          Journal:  Cancer Discov        ISSN: 2159-8274            Impact factor:   38.272


  9 in total

1.  A functional role for the B56 alpha-subunit of protein phosphatase 2A in ceramide-mediated regulation of Bcl2 phosphorylation status and function.

Authors:  Peter P Ruvolo; Warren Clark; Marc Mumby; Fengqin Gao; W Stratford May
Journal:  J Biol Chem       Date:  2002-04-02       Impact factor: 5.157

2.  A signalling pathway controlling c-Myc degradation that impacts oncogenic transformation of human cells.

Authors:  Elizabeth Yeh; Melissa Cunningham; Hugh Arnold; Dawn Chasse; Teresa Monteith; Giovanni Ivaldi; William C Hahn; P Todd Stukenberg; Shirish Shenolikar; Takafumi Uchida; Christopher M Counter; Joseph R Nevins; Anthony R Means; Rosalie Sears
Journal:  Nat Cell Biol       Date:  2004-03-14       Impact factor: 28.824

3.  Phenothiazines induce PP2A-mediated apoptosis in T cell acute lymphoblastic leukemia.

Authors:  Alejandro Gutierrez; Li Pan; Richard W J Groen; Frederic Baleydier; Alex Kentsis; Jason Marineau; Ruta Grebliunaite; Elena Kozakewich; Casie Reed; Francoise Pflumio; Sandrine Poglio; Benjamin Uzan; Paul Clemons; Lynn VerPlank; Frank An; Jason Burbank; Stephanie Norton; Nicola Tolliday; Hanno Steen; Andrew P Weng; Huipin Yuan; James E Bradner; Constantine Mitsiades; A Thomas Look; Jon C Aster
Journal:  J Clin Invest       Date:  2014-01-09       Impact factor: 14.808

4.  Activation of tumor suppressor protein PP2A inhibits KRAS-driven tumor growth.

Authors:  Jaya Sangodkar; Abbey Perl; Rita Tohme; Janna Kiselar; David B Kastrinsky; Nilesh Zaware; Sudeh Izadmehr; Sahar Mazhar; Danica D Wiredja; Caitlin M O'Connor; Divya Hoon; Neil S Dhawan; Daniela Schlatzer; Shen Yao; Daniel Leonard; Alain C Borczuk; Giridharan Gokulrangan; Lifu Wang; Elena Svenson; Caroline C Farrington; Eric Yuan; Rita A Avelar; Agnes Stachnik; Blake Smith; Vickram Gidwani; Heather M Giannini; Daniel McQuaid; Kimberly McClinch; Zhizhi Wang; Alice C Levine; Rosalie C Sears; Edward Y Chen; Qiaonan Duan; Manish Datt; Shozeb Haider; Avi Ma'ayan; Analisa DiFeo; Neelesh Sharma; Matthew D Galsky; David L Brautigan; Yiannis A Ioannou; Wenqing Xu; Mark R Chance; Michael Ohlmeyer; Goutham Narla
Journal:  J Clin Invest       Date:  2017-05-15       Impact factor: 14.808

5.  FTY720, a new alternative for treating blast crisis chronic myelogenous leukemia and Philadelphia chromosome-positive acute lymphocytic leukemia.

Authors:  Paolo Neviani; Ramasamy Santhanam; Joshua J Oaks; Anna M Eiring; Mario Notari; Bradley W Blaser; Shujun Liu; Rossana Trotta; Natarajan Muthusamy; Carlo Gambacorti-Passerini; Brian J Druker; Jorge Cortes; Guido Marcucci; Ching-Shih Chen; Nicole M Verrills; Denis C Roy; Michael A Caligiuri; Clara D Bloomfield; John C Byrd; Danilo Perrotti
Journal:  J Clin Invest       Date:  2007-09       Impact factor: 14.808

6.  Protein phosphatase 2A regulatory subunit B56alpha associates with c-myc and negatively regulates c-myc accumulation.

Authors:  Hugh K Arnold; Rosalie C Sears
Journal:  Mol Cell Biol       Date:  2006-04       Impact factor: 4.272

Review 7.  Therapeutic targeting of PP2A.

Authors:  Caitlin M O'Connor; Abbey Perl; Daniel Leonard; Jaya Sangodkar; Goutham Narla
Journal:  Int J Biochem Cell Biol       Date:  2017-10-26       Impact factor: 5.085

Review 8.  RNA splicing factors as oncoproteins and tumour suppressors.

Authors:  Heidi Dvinge; Eunhee Kim; Omar Abdel-Wahab; Robert K Bradley
Journal:  Nat Rev Cancer       Date:  2016-06-10       Impact factor: 60.716

9.  Mutations in the RNA Splicing Factor SF3B1 Promote Tumorigenesis through MYC Stabilization.

Authors:  Zhaoqi Liu; Akihide Yoshimi; Jiguang Wang; Hana Cho; Stanley Chun-Wei Lee; Michelle Ki; Lillian Bitner; Timothy Chu; Harshal Shah; Bo Liu; Anthony R Mato; Peter Ruvolo; Giulia Fabbri; Laura Pasqualucci; Omar Abdel-Wahab; Raul Rabadan
Journal:  Cancer Discov       Date:  2020-03-18       Impact factor: 38.272

  9 in total
  1 in total

1.  SF3B1 mutation in pancreatic cancer contributes to aerobic glycolysis and tumor growth through a PP2A-c-Myc axis.

Authors:  Jian-Yu Yang; Yan-Miao Huo; Min-Wei Yang; Yang Shen; De-Jun Liu; Xue-Liang Fu; Ling-Ye Tao; Rui-Zhe He; Jun-Feng Zhang; Rong Hua; Shu-Heng Jiang; Yong-Wei Sun; Wei Liu
Journal:  Mol Oncol       Date:  2021-05-03       Impact factor: 6.603

  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.